PWG
WST icon

Portside Wealth Group’s West Pharmaceutical WST Stock Holding History

Portside Wealth Group’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$550K Sell
1,532
-108
-7% -$33K 0.06% 284
2026
Q1 		$411K Sell
1,640
-365
-18% -$90.8K 0.06% 297
2025
Q4 		$552K Sell
2,005
-530
-21% -$145K 0.07% 234
2025
Q3 		$665K Buy
2,535
+22
+0.9% +$5.35K 0.09% 218
2025
Q2 		$550K Sell
2,513
-785
-24% -$168K 0.08% 230
2025
Q1 		$738K Buy
3,298
+203
+7% +$55.9K 0.12% 188
2024
Q4 		$1.01M Buy
3,095
+76
+3% +$23.9K 0.17% 131
2024
Q3 		$906K Buy
3,019
+204
+7% +$62.5K 0.15% 149
2024
Q2 		$927K Sell
2,815
-118
-4% -$41.7K 0.18% 130
2024
Q1 		$1.16M Buy
2,933
+258
+10% +$95.4K 0.21% 116
2023
Q4 		$942K Buy
2,675
+33
+1% +$11.7K 0.18% 130
2023
Q3 		$994K Sell
2,642
-55
-2% -$21.3K 0.19% 117
2023
Q2 		$1.03M Buy
+2,697
New +$963K 0.19% 121

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Portside Wealth Group's WST Position: Q2 2026 in Review

Portside Wealth Group reduced its West Pharmaceutical (WST) stake by 6.6% in Q2 2026, selling an estimated $33K and leaving 1,532 shares worth $550K. The position accounts for 0.06% of the portfolio, ranked #284.

Portside Wealth Group first reported a position in WST in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.16M in Q1 2024. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Portside Wealth Group held 1,532 shares of West Pharmaceutical worth $550K as of Q2 2026.
  • Portside Wealth Group sold 108 West Pharmaceutical shares in Q2 2026, an estimated $33K.
  • West Pharmaceutical made up 0.06% of Portside Wealth Group's portfolio in Q2 2026, its #284 holding.
  • Portside Wealth Group first reported a position in West Pharmaceutical in Q2 2023 and has held it in 13 quarters since.
  • Portside Wealth Group's West Pharmaceutical position peaked at $1.16M in Q1 2024.
  • 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Portside Wealth Group's 13F filing for Q2 2026, filed 14 Jul 2026.